1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study 2 RESEARCH METHODOLOGY 3 EXECUTIVE SUMMARY 4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Rise in Prevalence of Cancer and Cardiac Disorders 4.2.2 Increase in Technological Advancements 4.2.3 Growth in the Applications of Nuclear Medicine and Imaging 4.3 Market Restraints 4.3.1 High Cost of Techniques 4.3.2 Short Half-life of Radiopharmaceuticals 4.4 Porter's Five Force Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry 5 MARKET SEGMENTATION 5.1 Product 5.1.1 Equipment 5.1.1.1 Single Photon-emission Computed Tomography (SPECT) 5.1.1.2 Positron-emission Tomography (PET) 5.1.2 Radioisotope 5.1.2.1 SPECT Radioisotopes 5.1.2.1.1 Technetium-99m (TC-99m) 5.1.2.1.2 Thallium-201 (TI-201) 5.1.2.1.3 Gallium (Ga-67) 5.1.2.1.4 Iodine (I-123) 5.1.2.1.5 Other SPECT Radioisotopes 5.1.2.2 PET Radioisotopes 5.1.2.2.1 Fluorine-18 (F-18) 5.1.2.2.2 Rubidium-82 (RB-82) 5.1.2.2.3 Other PET Radioisotopes 5.2 Application 5.2.1 SPECT Applications 5.2.1.1 Orthopedics 5.2.1.2 Thyroid 5.2.1.3 Cardiology 5.2.1.4 Other SPECT Applications 5.2.2 PET Applications 5.2.2.1 Oncology 5.2.2.2 Cardiology 5.2.2.3 Neurology 5.2.2.4 Other PET Applications 6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 ATOX CO. Ltd 6.1.2 Bracco Imaging SpA 6.1.3 CANON INC. 6.1.4 Fujifilm (FUJIFILM Toyama Chemical Co. Ltd) 6.1.5 GE HEALTHCARE 6.1.6 IBA Radiopharma Solutions 6.1.7 JFE Engineering Corporation 6.1.8 Koninklijke Philips NV 6.1.9 Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd) 6.1.10 Siemens Healthineers 7 MARKET OPPORTUNITIES AND FUTURE TRENDS

- ATOX CO. Ltd - Bracco Imaging SpA - CANON INC. - Fujifilm (FUJIFILM Toyama Chemical Co. Ltd) - GE HEALTHCARE - IBA Radiopharma Solutions - JFE Engineering Corporation - Koninklijke Philips NV - Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd) - Siemens Healthineers